Webinar Date/Time: Thu, Aug 17, 2023 10:00 AM EDT
Cancer is a leading cause of death worldwide. Access, equity, and inclusion when developing and deploying new solutions to combat this disease remain paramount. Cancer Moonshot's new CancerX public-private partnership uses a three-pronged approach to generate impact in cancer research and care. This includes conducting pre-competitive evidence generation, establishing an accelerator cohort, and leading demonstration projects. How can technology serve as an enabler in the CancerX project? How can technology address barriers to access for cancer patients in obtaining the treatment options they need?
Register Free: https://www.pharmexec.com/pe_w/disparities-in-cancer-care
Event Overview:
Maintaining HIPAA compliance is essential for clinical and health science researchers worldwide who handle protected health information (PHI) to protect patient privacy and ensure research is conducted ethically. Oracle offers a secure cloud platform that meets HIPAA requirements, providing researchers with peace of mind that the data is protected and HIPAA compliant. Oracle achieves HIPAA compliance through ongoing practices and standards, such as encryption of data at rest and in transit, testing, and certifying physical security, requiring all HIPAA-compliant tenancies to have a business associate agreement in place, monitoring security settings and traffic flow, and undertaking continual security awareness and HIPAA trainings.
In this session, you’ll learn about the HIPAA compliance landscape overall and how Oracle supports HIPAA compliance for researchers, allowing them to focus on their research while maintaining patient trust and avoiding the risk of costly penalties and reputational damage.
Key Learning Objectives:
Who Should Attend:
In this webinar we will explore:
Speakers
JENNIFER GOLDSACK
CEO
Digital Medicine Society (DiMe)
Jennifer C. Goldsack co-founded and serves as the CEO of the Digital Medicine Society (DiMe), a 501(c)(3) non-profit organization dedicated to advancing digital medicine to optimize human health. Jennifer’s research focuses on applied approaches to the safe, effective, and equitable use of digital technologies to improve health, healthcare, and health research. She is a member of the Roundtable on Genomics and Precision Health at the National Academies of Science, Engineering and Medicine and serves on the World Economic Forum Global Leadership Council on mental health.
STEPHEN KONYA
Senior Advisor
Office for the National Coordinator for Health Information Technology
Stephen Konya serves as the Senior Advisor to the Deputy National Coordinator, and Innovation Portfolio Lead for the Office of the National Coordinator for Health IT (ONC), U.S. Department of Health and Human Services (HHS). In addition to shaping the Agency’s long-term strategy, he also serves as the primary liaison to the White House Office of Science and Technology Policy (OSTP) and the external healthcare startup and investor community.
Furthermore, Mr. Konya also leads the Digital Health Innovation Workgroup under the Federal Health IT Coordinating Council, an interagency collaboration community comprised of innovation representatives from 40 other federal agencies. In addition to currently serving as the primary Federal Govt lead and Co-Founder for CancerX, Mr. Konya has previously led several other key federal projects, including the HHS PandemicX Innovation Accelerator, the national Health IT Playbook, the ONC Patient Engagement Playbook for Providers, the SMART App Gallery, the FHIR at Scale Taskforce (FAST) Initiative, and is a founding Co-Chair of the Together.Health Collaborative.
EDMONDO ROBINSON
Chief Digital Officer
Moffitt Cancer Center
Dr. Robinson leads Moffitt’s Center for Digital Health which leverages the tools of IT, Health Data Services, Clinical Informatics and Digital Innovation to expand Moffitt’s ecosystem to deliver on consumer-oriented, real-world solutions for clinical practice, research, education, and administrative processes. In addition, he cares for Moffitt patients as part of the Internal and Hospital Medicine Program which includes teaching students and trainees. Previously, Dr. Robinson was the Chief Transformation Officer and Senior Vice President of Consumerism at ChristianaCare, one of the largest health systems in the mid-Atlantic.
Dr. Robinson is an associate professor at the University of South Florida’s Morsani College of Medicine. He serves as Chair of the National Advisory Council for the Agency for Healthcare Research and Quality and on the Board of Ardent Health. He is also a fellow of the American College of Physicians, a senior fellow of the Society of Hospital Medicine, and an Aspen Institute Health Innovators Fellow. He holds a medical degree from the David Geffen School of Medicine at the University of California, Los Angeles; an MBA with an emphasis in health care management from the Wharton School at the University of Pennsylvania; and a master’s degree in health policy research also from the University of Pennsylvania.
SHRUTI IYER
Principal Innovation Architect
Oracle
Shruti Iyer is a Principal Innovation Architect supporting Clinical Innovation in the Health Sciences Global Business Unit at Oracle. Shruti has had over seven years of experience at Medtronic as a subject matter expert in end-to-end medical device product development focusing on remote monitoring solutions for late-stage heart failure patients. Shruti has an M.S. in Medical Device Innovation from the University of Minnesota-Twin Cities where she was a Technological Leadership Institute Fellow. She is energized about driving complex and critical decisions in a highly regulated environment and is a thought leader with passion to empower patients to be in control of their health.
Register Free: https://www.pharmexec.com/pe_w/disparities-in-cancer-care
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
ROI and Rare Disease: Retooling the ‘Gene’ Value Machine
November 14th 2024Framework proposes three strategies designed to address the unique challenges of personalized and genetic therapies for rare diseases—and increase the probability of economic success for a new wave of potential curative treatments for these conditions.
Cell and Gene Therapy Check-in 2024
January 18th 2024Fran Gregory, VP of Emerging Therapies, Cardinal Health discusses her career, how both CAR-T therapies and personalization have been gaining momentum and what kind of progress we expect to see from them, some of the biggest hurdles facing their section of the industry, the importance of patient advocacy and so much more.